Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Sold by Clark Capital Management Group Inc.

Clark Capital Management Group Inc. decreased its position in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 16.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 46,200 shares of the medical equipment provider's stock after selling 8,947 shares during the period. Clark Capital Management Group Inc. owned about 0.07% of Lantheus worth $4,133,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Deutsche Bank AG boosted its holdings in Lantheus by 17.5% during the fourth quarter. Deutsche Bank AG now owns 274,134 shares of the medical equipment provider's stock worth $24,524,000 after buying an additional 40,866 shares in the last quarter. Diker Management LLC boosted its holdings in Lantheus by 57.4% during the fourth quarter. Diker Management LLC now owns 8,222 shares of the medical equipment provider's stock worth $736,000 after buying an additional 3,000 shares in the last quarter. Driehaus Capital Management LLC boosted its holdings in Lantheus by 6.6% during the fourth quarter. Driehaus Capital Management LLC now owns 370,661 shares of the medical equipment provider's stock worth $33,159,000 after buying an additional 23,036 shares in the last quarter. Cresset Asset Management LLC boosted its holdings in Lantheus by 3.3% during the fourth quarter. Cresset Asset Management LLC now owns 30,182 shares of the medical equipment provider's stock worth $2,700,000 after buying an additional 976 shares in the last quarter. Finally, Cetera Investment Advisers boosted its holdings in Lantheus by 22.7% during the fourth quarter. Cetera Investment Advisers now owns 23,358 shares of the medical equipment provider's stock worth $2,090,000 after buying an additional 4,320 shares in the last quarter. Hedge funds and other institutional investors own 99.06% of the company's stock.

Analysts Set New Price Targets

A number of research firms recently commented on LNTH. StockNews.com raised shares of Lantheus from a "hold" rating to a "buy" rating in a report on Thursday. B. Riley decreased their price objective on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a report on Friday, March 21st. Truist Financial decreased their price objective on shares of Lantheus from $127.00 to $117.00 and set a "buy" rating on the stock in a report on Thursday. Finally, JMP Securities restated a "market outperform" rating and set a $112.00 target price on shares of Lantheus in a research report on Tuesday, January 14th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Lantheus presently has an average rating of "Buy" and an average price target of $132.67.

Insider Activity

In other news, CFO Robert J. Jr. Marshall sold 10,000 shares of Lantheus stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $100.52, for a total value of $1,005,200.00. Following the transaction, the chief financial officer now directly owns 113,860 shares of the company's stock, valued at $11,445,207.20. The trade was a 8.07% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Mary Anne Heino sold 53,107 shares of Lantheus stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the transaction, the director now directly owns 440,399 shares in the company, valued at $41,551,645.65. This represents a 10.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 63,109 shares of company stock valued at $6,016,046 over the last 90 days. Insiders own 2.00% of the company's stock.

Lantheus Stock Up 1.8%

Shares of NASDAQ:LNTH traded up $1.42 during trading on Friday, reaching $81.86. The stock had a trading volume of 1,561,278 shares, compared to its average volume of 968,940. The business has a fifty day moving average price of $99.57 and a 200-day moving average price of $94.14. The stock has a market cap of $5.61 billion, a P/E ratio of 13.62 and a beta of 0.23. Lantheus Holdings, Inc. has a fifty-two week low of $75.00 and a fifty-two week high of $126.89.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share for the quarter, missing analysts' consensus estimates of $1.64 by ($0.11). The firm had revenue of $372.76 million during the quarter, compared to analyst estimates of $377.37 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The business's quarterly revenue was up .8% on a year-over-year basis. During the same period in the prior year, the firm earned $1.69 EPS. As a group, equities analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.